Tillkännagivande • Jul 30
Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite Index AHI has been dropped from NASDAQ Composite Index Tillkännagivande • Apr 16
Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,000,000
Price\Range: AUD 0.0675
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Feb 27
Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: AUD 0.1
Transaction Features: Subsequent Direct Listing Tillkännagivande • Dec 02
Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation Assessment Advanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product. Tillkännagivande • Nov 06
Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,749,996
Price\Range: AUD 0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,245,454
Price\Range: AUD 0.11
Transaction Features: Subsequent Direct Listing Tillkännagivande • Nov 01
Advanced Health Intelligence Ltd. announced delayed 20-F filing On 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Tillkännagivande • Oct 19
Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023 Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023, at 10:30 W. Australia Standard Time. Location: Steinepreis Paganin, Level 4, 16 Milligan Street, Perth WA 6000 Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of remuneration report; to election of director Jacqueline yee; to re-election of director Dato low koon poh; to re-election of director Mike melby; to issue of shares to related party Nicholas prosser; to issue of shares to related party Mike melby; to approval of 7.1A mandate; to adoption of employee securities incentive plan; to ratification of prior issue of lender shares; to ratification of prior issue of consultant shares; to ratification of prior issue of supplier shares; to ratification of prior issue of placement shares listing rule 7.1; to ratification of prior issue of placement shares listing rule 7.1A; to ratification of prior issue of lead manager options; and to consider other issues. Tillkännagivande • Sep 14
Advanced Health Intelligence Ltd. announced that it has received AUD 1.5 million in funding Advanced Health Intelligence Ltd. announced a private placement of unsecured convertible loan facility for the gross proceeds of AUD 1,500,000 on September 12, 2023. The loan carry interest rate of 10% per annum and is compounded quarterly in arrears and will mature after 24 months from the date of signing. The investors may elect to redeem the outstanding principal amount and interest on the loans in cash on the Maturity Date. The loans and interest may be converted into fully paid ordinary shares at the investor’s election, at a conversion price equal to AUD 0.30 per share. The transaction is subject to shareholders approval. Tillkännagivande • Jun 15
Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million. Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: AUD 0.25
Discount Per Security: AUD 0.015
Transaction Features: Subsequent Direct Listing New Risk • Jun 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 76% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Share price has been highly volatile over the past 3 months (76% average daily change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (AU$494k revenue, or US$333k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap). Tillkännagivande • Dec 20
Advanced Health Intelligence Ltd. Announces Board Changes Advanced Health Intelligence Ltd. announced some changes at the company's Board of Directors. Former wellteq Digital Health Inc. Chair of the Finance and Audit committee, Ms Jacqueline Yee joins AHI's Board of Directors as a non-executive independent Director with effect from 20 December 2022. Ms Yee has an impressive background having spent over 30 years as an institutional finance professional out of New York, London, Amsterdam, Australia and currently resides in Singapore. Throughout her career to date, Ms Yee has been involved in over $25 billion in transaction value with a notable volume of work in the healthcare sector, including restructuring of 27 national hospitals and the drafting of Healthcare Investment Valuation Policy in New Zealand. With the addition of Ms Yee, Dr. Peter Vaughan has stepped down from the Board with effect from 16 December 2022. Tillkännagivande • Nov 01
Advanced Human Imaging Limited announced delayed 20-F filing On 10/31/2022, Advanced Human Imaging Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC. Tillkännagivande • Oct 31
Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022 Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022, at 12:00 W. Australia Standard Time. Location: Lucy Mame meeting room QT Perth Hotel 133 Murray Street, Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2022 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of Remuneration Report; to consider election of Director - Dr Katherine Iscoe; to consider election of Director - Peter Goldstein; to consider re-election of Director - Nicholas Prosser; to consider issue of shares to related party - Nicholas Prosser; and to consider other matters. Tillkännagivande • Jun 29
Advanced Human Imaging Ltd Appoints Peter Goldstein as Non-Executive Director Advanced Human Imaging Ltd. announced the appointment of Mr. Peter Goldstein as a non-executive director with effect from June 29, 2022. Mr. Goldstein has over 30 years of diverse and global entrepreneurial, client advisory and capital marketexperience. With a background in international business, he has worked across a range of markets andindustries, holding positions including investment banker, chairman, chief executive officer, director andadvisor to public, private, and emerging growth companies. Mr. Goldstein has achieved capital marketobjectives by drawing on his strengths in M&A, strategic planning and transaction structuring, as well as hisown entrepreneurial success. He has steered and completed initial public offerings (IPO), up-listing andreverse merger transactions, secured private placements and designed crowdfunding campaigns. Mr. Goldstein founded Exchange Listing, LLC to provide growth companies with a cost-effective one-stopstrategic planning and implementation service to list on senior exchanges such as NASDAQ, NYSE andNEO. Mr. Goldstein is the Founder and CEO of Grandview Capital Partners Inc., providing M&A, financial,operational, and organizational consulting services to businesses globally in a wide range of industries. MrGoldstein previously founded Grandview Capital Inc., a boutique investment bank, where he served asmanaging director of investment banking.Mr Goldstein began his entrepreneurial career as the Founder and CEO of a specialty food distributor, whichpioneered the farm-to-table organic produce industry in top-tier New York City restaurants. Mr. Goldsteinhas an MBA in International Business from the University of Miami and held Series 7, 24, 79, 99 and 66registrations with FINRA.Mr. Goldstein has been published across the finance industry as well as featured in Forbes as a member ofthe Forbes Finance Council. Mr. Goldstein, a resident of Florida, U.S.A. Tillkännagivande • Jun 02
Advanced Human Imaging Limited to Be Deleted from Other OTC Advanced Human Imaging Limited's ordinary shares will be deleted from Other OTC effective June 2, 2022. The deletion is due to inactive security. Tillkännagivande • May 28
Advanced Human Imaging Limited Announces Resignation of Edward Greissing Jr as Director Advanced Human Imaging Ltd. announced that Mr. Edward Greissing Jr has resigned from the Board of Directors, with effect from 26 May 2022. Tillkännagivande • Feb 16
Advanced Human Imaging Limited Appoints Dr. Katherine Iscoe as Director Advanced Human Imaging Limited announced that the appointment of Dr. Katherine Iscoe as director. The date of appointment is February 15, 2022. 